Patents Assigned to Protiva Biotherapeutics Inc.
-
Patent number: 8822668Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: June 26, 2013Date of Patent: September 2, 2014Assignee: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20140134260Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid in vivo. The compositions of the present invention are highly potent, thereby allowing effective know-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: October 1, 2013Publication date: May 15, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Lorne Palmer, Magdalena Maslowski, Ian MacLachlan
-
Publication number: 20140065228Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: June 26, 2013Publication date: March 6, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20140044772Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: November 21, 2012Publication date: February 13, 2014Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventor: Protiva Biotherapeutics, INC.
-
Publication number: 20130303587Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: June 30, 2011Publication date: November 14, 2013Applicant: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 8569256Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: June 30, 2010Date of Patent: October 29, 2013Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Lorne Palmer, Magdalena Maslowski, Ian MacLachlan
-
Patent number: 8513403Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: April 26, 2012Date of Patent: August 20, 2013Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Patent number: 8492359Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: October 5, 2011Date of Patent: July 23, 2013Assignee: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20130178511Abstract: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.Type: ApplicationFiled: July 17, 2012Publication date: July 11, 2013Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Snorri S. Thorgeirsson, Yun-Han Lee
-
Publication number: 20130172405Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).Type: ApplicationFiled: December 21, 2012Publication date: July 4, 2013Applicant: PROTIVA BIOTHERAPEUTICS INC.Inventor: PROTIVA BIOTHERAPEUTICS INC.
-
Patent number: 8466122Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: September 16, 2011Date of Patent: June 18, 2013Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin
-
Patent number: 8455455Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target Lassa virus (LASV) or tissue factor (TF) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating hemorraghic fever).Type: GrantFiled: March 31, 2011Date of Patent: June 4, 2013Assignees: Protiva Biotherapeutics, Inc., The United States Army Medical Research and Materiel CommandInventors: Marjorie Robbins, Susan de Jong, Vandana Sood, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20130123339Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: May 12, 2011Publication date: May 16, 2013Applicant: PROTIVA BIOTHERAPEUTICS INCInventors: James Heyes, Mark Wood, Alan Martin, Amy C.H. Lee, Adam Judge, Marjorie Robbins, Ian MacLachlan
-
Publication number: 20130122104Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: August 3, 2012Publication date: May 16, 2013Applicant: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20130123338Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: May 12, 2011Publication date: May 16, 2013Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin
-
Publication number: 20130116307Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: May 12, 2011Publication date: May 9, 2013Applicant: PROTIVA BIOTHERAPEUTICS INC.Inventors: James Heyes, Mark Wood, Alan Martin
-
Publication number: 20130065939Abstract: The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer.Type: ApplicationFiled: September 23, 2010Publication date: March 14, 2013Applicants: Protiva Biotherapeutics, Inc., Department of Health and Human ServicesInventors: Adam Judge, Yun-Han Lee, Ian MacLachlan, Snorri S. Thorgeirsson
-
Publication number: 20130064894Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: August 30, 2012Publication date: March 14, 2013Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Alan Martin, James Heyes, Mark Wood
-
Publication number: 20130022649Abstract: The present invention provides methods of preventing, decreasing, or inhibiting the degradation of cationic lipids and/or active agents (e.g., therapeutic nucleic acids) present in lipid particles, compositions comprising lipid particles stabilized by these methods, methods of making these lipid particles, and methods of delivering and/or administering these lipid particles, e.g., for the treatment of a disease or disorder.Type: ApplicationFiled: December 1, 2010Publication date: January 24, 2013Applicant: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, James Heyes, Adam Judge, Stephen Reid, Ian MacLachlan
-
Publication number: 20120328668Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: April 26, 2012Publication date: December 27, 2012Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge